Periodically repeated rituximab administrations in children with refractory nephrotic syndrome: 2-year multicenter observational study

[1] Iijima K(2017)Rituximab for nephrotic syndrome in children Clin Exp Nephrol 21 193-202

[2] Sako M(2016)Anti-CD20 antibodies for idiopathic nephrotic syndrome in children Clin J Am Soc Nephrol 11 710-720

[3] Nozu K(2012)Rituximab in steroid-dependent idiopathic nephrotic syndrome in childhood—follow-up after CD19 recovery Nephrol Dial Transplant 27 1083-1089

[4] Ravani P(2013)Rituximab is a safe and effective long-term treatment for children with steroid and calcineurin inhibitor-dependent idiopathic nephrotic syndrome Kidney Int 84 1025-1033

[5] Bonanni A(2014)Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial Lancet 384 1273-1281

[6] Rossi R(2013)Survey of rituximab treatment for childhood-onset refractory nephrotic syndrome Pediatr Nephrol 28 257-264

[7] Caridi G(2017)Long-term outcome of childhood-onset complicated nephrotic syndrome after a multicenter, double-blind, randomized, placebo-controlled trial of rituximab Pediatr Nephrol 32 2071-2078

[8] Ghiggeri GM(2011)Maintenance therapy with mycophenolate mofetil after rituximab in pediatric patients with steroid-dependent nephrotic syndrome Pediatr Nephrol 26 1823-1828

[9] Sellier-Leclerc AL(2013)Cyclosporine versus mycophenolate mofetil for maintenance of remission of steroid-dependent nephrotic syndrome after a single infusion of rituximab Eur J Pediatr 172 513-518

[10] Baudouin V(2011)Short-term effects of rituximab in children with steroid- and calcineurin-dependent nephrotic syndrome: a randomized controlled trial Clin J Am Soc Nephrol 6 1308-1315

[1] Iijima K(2017)Rituximab for nephrotic syndrome in children Clin Exp Nephrol 21 193-202

[2] Sako M(2016)Anti-CD20 antibodies for idiopathic nephrotic syndrome in children Clin J Am Soc Nephrol 11 710-720

[3] Nozu K(2012)Rituximab in steroid-dependent idiopathic nephrotic syndrome in childhood—follow-up after CD19 recovery Nephrol Dial Transplant 27 1083-1089

[4] Ravani P(2013)Rituximab is a safe and effective long-term treatment for children with steroid and calcineurin inhibitor-dependent idiopathic nephrotic syndrome Kidney Int 84 1025-1033

[5] Bonanni A(2014)Rituximab for childhood-onset, complicated, frequently relapsing nephrotic syndrome or steroid-dependent nephrotic syndrome: a multicentre, double-blind, randomised, placebo-controlled trial Lancet 384 1273-1281

[6] Rossi R(2013)Survey of rituximab treatment for childhood-onset refractory nephrotic syndrome Pediatr Nephrol 28 257-264

[7] Caridi G(2017)Long-term outcome of childhood-onset complicated nephrotic syndrome after a multicenter, double-blind, randomized, placebo-controlled trial of rituximab Pediatr Nephrol 32 2071-2078

[8] Ghiggeri GM(2011)Maintenance therapy with mycophenolate mofetil after rituximab in pediatric patients with steroid-dependent nephrotic syndrome Pediatr Nephrol 26 1823-1828

[9] Sellier-Leclerc AL(2013)Cyclosporine versus mycophenolate mofetil for maintenance of remission of steroid-dependent nephrotic syndrome after a single infusion of rituximab Eur J Pediatr 172 513-518

[10] Baudouin V(2011)Short-term effects of rituximab in children with steroid- and calcineurin-dependent nephrotic syndrome: a randomized controlled trial Clin J Am Soc Nephrol 6 1308-1315